This document discusses the use of monoclonal antibodies for cancer therapy. It provides background on conventional chemotherapy and highlights limitations. It then covers the history and development of monoclonal antibodies, including their production and mechanisms of targeting cancer cells through antigen cross-linking, activating death receptors, or delivering cytotoxic agents. Specific examples of toxin-immunoconjugates and antibody-directed enzyme prodrug therapy are described. The monoclonal antibody Rituximab is discussed as the first FDA-approved therapeutic monoclonal antibody for cancer.